Drug Manufacturers - Specialty & Generic

​At its Lowest Moment, Is Teligent (TLGT) Actually Closer to an Inflection Point Than Ever?

​At its Lowest Moment, Is Teligent (TLGT) Actually Closer to an Inflection Point Than Ever?

Stephen L Kanaval | |

Does Teligent have the R&D to turn things around?

Marijuana Stocks Ready for Another Massive Rally?

Chris Vermeulen | |

​Our research team has been actively discussing the potential that the entire marijuana stock sector could be setting up for another upside price rally.

Amneal Gets Approval for Generic Version of Exelon Patch for Dementia

Edward Kim | |

First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).

Osmotica Pharmaceuticals' $125 Million IPO Expected Next Week

Edward Kim | |

$246 million in revenue in 2017 from specialty neurology, women's health and generics. Phase 3 in MS and droopy eyelid (Image: Osmotica Pharmaceuticals).

​Nemus Biosciences is Working with Cannabinoids to Treat Glaucoma

Stephen L Kanaval | |

For our aging population, Glaucoma is a very large market.

​PreveCeutical Announces the Appointment of Dr. Harendra Parekh as Chief Research Officer

Spotlight Companies | |

PreveCeutical Medical Inc. is pleased to announce the appointment of Dr. Harendra (“Harry”) Parekh, Ph.D., BSc., Hons I, as Chief Research Officer (“CRO”).

​Immunovaccine's (IMV: CA) Lead Immuno-Oncology Candidate to Enter Phase 2 Clinical Trial In Dlbcl in Combination with Approved Anti-Pd-1 Drug

Spotlight Companies | |

ImmunoVaccine (IMV: CA) to conduct phase 2 trial on DPX-Survivac.

NovaBay (NBY) Eyeing 60% Revenue Growth in 2017

Edward Kim | |

NovaBay Pharmaceuticals (NBY) hit positive cash flow in December 2016 as it promised, via sales of its Avenova antimicrobial eye care product. and has guided investors to 60% revenue growth in 2017.

Jaguar Animal Health (JAGX) Continues its Sizzling Year +82%

Edward Kim | |

Shares in Jaguar Animal Health, Inc. (JAGX) an animal health company focused on developing and commercializing first-in-class gastrointestinal products has had a sizzling 2017 and it's run continues today.

Novan, Inc (NOVN) Crushed on Weak Phase 3 News. Down Over 75%

Matthew Paul | |

While the results for this Phase 3 trials we not what was expected, there is reason to be optimistic, as Stasko suggested. The results from NI-AS301 doesn’t necessarily mean the drug is dead.

Humanity. 2.0 - Opening Address at the Vatican

The opening address was delivered by Rev. Philip Larrey, Chairman of. Humanity 2.0, and Matthew. Sanders, CEO & Founder of Humanity 2.0.


Sohn Investment Conference

Wall Street’s best and brightest investors participate in this unique, “must attend” event to share their expertise with an audience of more than 3,000 people, comprised of portfolio managers, asset…

Learn more